Biotech

All Articles

Merck ceases phase 3 TIGIT trial in bronchi cancer cells for impossibility

.Merck &amp Co.'s TIGIT program has suffered an additional setback. Months after shuttering a stage ...

After a challenging year, Exscientia folds up right into Recursion

.After a year described through pipeline hairstyles, the shift of its CEO and discharges, Exscientia...

Cullinan, after $25M package, restore bispecific to Port

.Cullinan Therapy was blown away sufficient along with Harbour BioMed's bispecific immune activator ...

A more detailed take a look at Brutal Biotech's Ferocious 15

.Within this full week's episode of "The Leading Line," our team are actually diving in to Brutal Bi...

Lilly experiences phase 2 failing of tau-targeting med

.The confetti is actually still flying coming from Eli Lilly's celebration celebrating the commendat...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Accept to this week's Chutes &amp Ladders, our roundup of substantial management hirings, firings a...

Lykos will certainly talk to FDA to rethink its own choice following being rejected of MDMA therapy for post-traumatic stress disorder

.Observing an unsatisfactory revealing for Lykos Therapies' MDMA applicant for post-traumatic stress...

AN 2 halves census, stops stage 3 trial after data dissatisfy

.AN2 Therapies is actually re-thinking its own company in feedback to poor midphase information, swe...

Merck spends $700M for bispecific, spying autoimmune opening and opportunity to test Amgen in cancer

.Merck &amp Co. is spending $700 thousand upfront to test Amgen in a blood cancer market. The packag...

Gilead pays for J&ampJ $320M to go out licensing offer for seladelpar

.Along With Gilead Sciences on the verge of an FDA choice for its own liver ailment medication selad...